VR headset and eye drops join forces to fight childhood nearsightedness

NCT ID NCT07724210

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether combining a daily 18-minute virtual reality training session with low-dose atropine eye drops can slow the worsening of nearsightedness in children aged 6 to 12. Participants will also wear special glasses that provide defocus to the peripheral vision. The study compares this triple approach against atropine plus the special glasses alone, tracking changes in eye length and prescription over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
virtual reality-based digital defocus training combined with 0.02% atropine eye drops
What this could lead to
If effective, this combination approach could offer a new, non-invasive way to slow myopia progression in children, reducing the need for stronger glasses or future eye problems.
What could go wrong
This is a small, early-stage trial with only 100 participants, and the added benefit of VR training over atropine alone is unproven. Side effects from atropine may include light sensitivity or blurred near vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, National Engineering Research Center for Ophthalmology

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.